But the move by the Rams, along with a, signals what’s ahead with the eventual spread of legalized sports betting in the wake of a 2018 that overturned the Professional and Amateur Sports Protection Act. Tally is a free-to-play predictions platform, not a gambling app. Fans, playing on the web or through the Rams’ mobile app, earn points for every correct prediction and those over 18 can compete for prizes such as game tickets, field passes and autographed merchandise. The intention is to engage fans to make real-time predictions as the action unfolds on the field. The Rams launched “Pick’em” for use during a pre-season game against the Oakland Raiders. The best way to do so could be through a new mobile experience from the NFL team that is powered by, the startup that was founded by Wilson. 3 this season, fans might want to predict how many touchdowns quarterback Russell Wilson will throw against his division rival on that day. When the Seattle Seahawks take on the Los Angeles Rams on Oct. Seattle Seahawks quarterback Russell Wilson, right, with Jason LeeKeenan, CEO of Tally, in Seattle in 2018. Joseph Health, which would give researchers access to a more representative population. In the future, ISB intends to partner with Providence St. “It is a bit of a biased sampling,” said Gibbons. One disadvantage of the dataset is that it skewed toward white, health-conscious people, who were more likely to be Arivale’s customers.
“We’re trying to build a real map that can lead to actionable insights of how to manipulate the microbiome,” Gibbons said. With the help of Arivale’s data, ISB researchers think more microbiome-related insights can be found. People with low diversity tended to have diarrhea and inflammation, whereas those with very high diversity tended to be constipated or have toxins in the blood. They also found what they believe to be a “Goldilocks zone” of gut diversity. The ISB study is a “beautiful example” of how personal data clouds can give new insights into biology and disease, Hood told GeekWire in an email. Arivale customers gave permission for their data to be used for research, and the information was anonymized. The researchers were able to train a model to predict which individuals are likely to have very low microbiome diversity by looking at 11 blood metabolites. That resource gave Price and Gibbons extensive data on hundreds of former Arivale customers who had their microbiomes sequenced and their blood tested, among other tests. Lee Hood, who co-founded both Arivale and ISB, rescued much of the data and technology from the startup and brought it to ISB. In April after it failed to find a market for its pricey service. To create the test, researchers leaned heavily on data compiled by Arivale, a Seattle startup that aimed to help people become healthier and avoid disease through wellness. Gibbons thinks that a blood test could pre-screen patients at risk of recurring C. diff can be treated with a fecal transplant, but those are only administered after antibiotics have failed. “If you could avoid that cycle, you could not only decrease the cost of healthcare, you would actually be saving lives and producing a lot less suffering.” “Getting these recurrent infections is super hard on patients,” Gibbons said. diff is a potentially life-threatening bacterium that comes back in nearly a third of patients following antibiotic treatment. Low microbiome diversity is a strong risk factor for patients with recurring Clostridium difficile (C. But there are specific cases in which it does seem to be a huge risk factor,” said, who worked with on the study, which was published today in Nature Biotechnology. “There’s not a good correlation between diversity in and of itself and clinical health. That’s why ISB researchers decided to focus on the diversity of microbes. Given the relatively early stage of microbiome research, how useful insights from the gut can be. Others, including Seattle-based, are selling microbiome insights directly to consumers for overall health. Some are going after drug discovery for specific diseases, such as Finch Therapeutics and Maat Pharma. Microbiome startups have proliferated in recent years. Researchers at the (ISB) in Seattle have devised a new way to look into the state of your microbiome with a blood test. You just have to pay them - and send in a poop sample.īut it turns out that bottling feces isn’t the only way to gain insights into the gut. If you want to know what’s going on in your gut microbiome, the community of bacteria in our intestines that are tied to overall health, there are plenty of companies willing to help. Researchers at the Institute for Systems Biology in Seattle developed a way to test for microbiome diversity from a blood sample.